A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

  1. Sonneveld, P.
  2. Dimopoulos, M.A.
  3. Boccadoro, M.
  4. Quach, H.
  5. Ho, P.J.
  6. Beksac, M.
  7. Hulin, C.
  8. Antonioli, E.
  9. Leleu, X.
  10. Mangiacavalli, S.
  11. Perrot, A.
  12. Cavo, M.
  13. Belotti, A.
  14. Broijl, A.
  15. Gay, F.
  16. Mina, R.
  17. van de Donk, N.W.C.J.
  18. Katodritou, E.
  19. Schjesvold, F.
  20. Balari, A.S.
  21. Rosiñol, L.
  22. Delforge, M.
  23. Roeloffzen, W.
  24. Silzle, T.
  25. Vangsted, A.
  26. Einsele, H.
  27. Spencer, A.
  28. Hajek, R.
  29. Jurczyszyn, A.
  30. Lonergan, S.
  31. Ahmadi, T.
  32. Liu, Y.
  33. Wang, J.
  34. Vieyra, D.
  35. van Brummelen, E.M.J.
  36. Vanquickelberghe, V.
  37. Sitthi-Amorn, A.
  38. de Boer, C.J.
  39. Carson, R.
  40. Rodriguez-Otero, P.
  41. Bladé, J.
  42. Moreau, P.
  43. Show all authors +
Journal:
Future Oncology

ISSN: 1744-8301,  1479-6694

Year of publication: 2024

Type: Article

DOI: 10.1080/14796694.2024.2394323 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus